Literature DB >> 24830677

Acute respiratory failure during first cyclophosphamide infusion in a patient with systemic lupus erythematosus.

P Schjelderup1, T C El-Galaly, J B Frøkjær, T Ring.   

Abstract

We present a report of what we believe was an extremely rare case of hyperacute respiratory failure caused by first time exposure to cyclophosphamide in a 40-year-old woman with systemic lupus erythematosus. The patient was extensively evaluated for alternative etiologies with negative results. Treatment with methylprednisolone and high doses of human immunoglobulin resulted in gradual improvement of the patient's condition. We review the literature with regard to cyclophosphamide-induced lung toxicity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24830677     DOI: 10.1007/s00393-014-1381-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  9 in total

1.  Pulmonary fibrosis secondary to administration of mycophenolate mofetil.

Authors:  P Morrissey; R Gohh; P Madras; A P Monaco
Journal:  Transplantation       Date:  1998-05-27       Impact factor: 4.939

2.  Fatal pulmonary fibrosis occurring during treatment with cyclophosphamide.

Authors:  D A Burke; J C Stoddart; M K Ward; C G Simpson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-11

3.  Acute respiratory failure and pulmonary fibrosis secondary to administration of mycophenolate mofetil.

Authors:  D C Gross; T M Sasaki; M K Buick; J A Light
Journal:  Transplantation       Date:  1997-12-15       Impact factor: 4.939

Review 4.  Lung toxicity associated with cyclophosphamide use. Two distinct patterns.

Authors:  S W Malik; J L Myers; R A DeRemee; U Specks
Journal:  Am J Respir Crit Care Med       Date:  1996-12       Impact factor: 21.405

Review 5.  Pulmonary manifestations of systemic lupus erythematosus.

Authors:  Diane L Kamen; Charlie Strange
Journal:  Clin Chest Med       Date:  2010-09       Impact factor: 2.878

6.  Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

Authors:  Frédéric A Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani; Enrique de Ramon Garrido Ed; Maria Giovanna Danieli; Daniel Abramovicz; Daniel Blockmans; Alessandro Mathieu; Haner Direskeneli; Mauro Galeazzi; Ahmet Gül; Yair Levy; Peter Petera; Rajko Popovic; Radmila Petrovic; Renato Alberto Sinico; Roberto Cattaneo; Josep Font; Geneviève Depresseux; Jean-Pierre Cosyns; Ricard Cervera
Journal:  Arthritis Rheum       Date:  2002-08

7.  An investigation of the chest radiographs in a controlled trial of busulphan, cyclophosphamide, and a placebo after resection for carcinoma of the lung.

Authors:  H Stott; R Stephens; W Fox; G Simon; D C Roy
Journal:  Thorax       Date:  1976-06       Impact factor: 9.139

Review 8.  Cyclophosphamide and cancer: golden anniversary.

Authors:  Ashkan Emadi; Richard J Jones; Robert A Brodsky
Journal:  Nat Rev Clin Oncol       Date:  2009-09-29       Impact factor: 66.675

9.  Cyclophosphamide therapy and interstitial pulmonary fibrosis.

Authors:  A R Patel; P C Shah; H L Rhee; H Sassoon; K P Rao
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.